Finding nuance and solutions amongst the clutter
Finding the right cell/right compartment isn't easy - it requires persistence and dedication
It's time to look to the future beyond plain vanilla ADCs
Hats off to companies pursuing an emerging target in breast cancer
Important lessons learned from failure
The importance of T cell exhaustion and exploring ways to avoid it
Review of some of the key trials in breast cancer being showcased in Paris next month
What can we learn from various breast cancer trials?
Going beyond the obvious conclusion with anti-LAG3 therapy
What's worth following on the targeted therapy front in breast cancer? A look pipelines and new indications from SABCS
Post SABCS analysis of a key topic and cancer driver
A look at the KEYNOTE-522 and neoTRIP clinical trials in neoadjuvant TNBC
A look at tucatinib, margetuximab and trastuzumab deruxtecan in HER2+ advanced MBC
Interview with Syros Pharma CEO Dr Nancy Simonian
A rock around the breast cancer clock with cancer immunotherapies and targeted agents from SABCS18
A look at the latest CDK4/6 inhibitor data including the important phase 3 trial with ribociclib (MONALEESA-7).
2017 could well turn out to be a good year for HER2+ breast cancer with several new developments ongoing. We take a look...
How crowdsourcing data from breast cancer patients may help future clinical R&D
Will cancer stem cell therapeutics impact the lives of people with metastatic breast cancer?
SABCS16 expert interview on Inflammatory Breast Cancer with Dr Naoto Ueno from MD Anderson Cancer Center.
SABCS16 expert interview on the potential of circulating tumor DNA to change the treatment of cancer.
Second in our series of expert interviews from the 2016 San Antonio Breast Cancer Symposium features Dr Leisha Emens
First in a mini-series of expert interviews from the 2016 San Antonio Breast Symposium #SABCS16 with a leading researcher who has discovered a first-in-class compound with potential in metastatic breast cancer.
3 trends from SABCS16 that you may hear more about
Five promising new agents in development for the treatment of ER+ or HER2+ or triple negative breast cancer emerge from #SABCS15
Adding chemotherapy or an ADC boosts the immunogenic effects prior to checkpoint therapy in metastatic breast cancers
Biomarin have a good shot on goal with their PARP inhibitor talazoparib in gBRCA breast cancer
What's next in immuno-oncology: what are potential ways to tackle the patients who do not respond to checkpoint immunotherapy?
In the last post of 2014, it’s time to address some pertinent questions on triple negative breast cancer (TNBC).
There is a lot of interest in checkpoint inhibitors, do they look they will be effective in Triple Negative Breast Cancer?
The first readout from the I-SPY2 neoadjuvant breast cancer trial comes from the veliparib (PARP) arm.
A preview of some of the landmark trial data emerging from the 2013 San Antonio Breast Cancer Symposium
